COVAGEN

covagen-logo

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagenโ€™s lead FynomAb COVA322 is being developed for the t... reatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagenโ€™s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.

#People #Financial #Website #More

COVAGEN

Social Links:

Industry:
Biopharma Biotechnology Therapeutics

Founded:
2007-01-01

Address:
Schlieren, Zurich, Switzerland

Country:
Switzerland

Website Url:
http://www.covagen.com

Total Employee:
11+

Status:
Closed

Contact:
41 44 732 46 60

Total Funding:
106.63 M USD



Current Advisors List

anja-kรถnig_image

Anja Kรถnig Board Positions @ Covagen
Board_member

karl-nagler_image

Karl Nagler Board of Directors @ Covagen
Board_member

mounia-chaoui_image

Mounia Chaoui Board of Directors @ Covagen
Board_member

Current Employees Featured

raymond-hill_image

Raymond Hill
Raymond Hill Non-Executive Director @ Covagen
Non-Executive Director

Founder


julian-bertschinger_image

Julian Bertschinger

Investors List

seroba-life-sciences_image

Seroba Life Sciences

Seroba Life Sciences investment in Series B - Covagen

baxter-ventures_image

Baxter Ventures

Baxter Ventures investment in Series B - Covagen

gimv_image

Gimv

Gimv investment in Series B - Covagen

ventech-capital_image

Ventech

Ventech investment in Series B - Covagen

edmond-de-rothschild-investment-partners_image

Andera Partners

Andera Partners investment in Series B - Covagen

novartis-venture-fund_image

Novartis Venture Fund

Novartis Venture Fund investment in Series B - Covagen

mp-healthcare-venture-management-inc_image

MP Healthcare Venture Management

MP Healthcare Venture Management investment in Series B - Covagen

ascent-biomedical-ventures_image

Ascent Biomedical Ventures

Ascent Biomedical Ventures investment in Series B - Covagen

edmond-de-rothschild-private-equity_image

Edmond de Rothschild Private Equity

Edmond de Rothschild Private Equity investment in Series B - Covagen

ventech-capital_image

Ventech

Ventech investment in Series A - Covagen

Official Site Inspections

http://www.covagen.com

Unable to get host informations!!!

Loading ...

More informations about "Covagen" on Search Engine